Previous 10 | Next 10 |
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...
AlloVir press release ( NASDAQ: ALVR ): Q2 GAAP EPS of $0.69 beats by $1.42 . For the quarter ended June 30, 2022, net loss was $44.6 million or $0.69 per share, compared with a net loss of $37.6 million or $0.60 per share for the quarter ended June 30, 2021. For...
Three Phase 3 Posoleucel Registrational Trials Continue to Expand Globally, Enrolling Patients in the U.S., Europe and Asia Company Is On Track to Release Final Results of Posoleucel Phase 2 Multi-Virus Prevention Study at Year-End and Topline Results of Phase 2 BKV Treatment ...
Community Health Systems CYH -45% on Q2 results. Coursera COUR -37% on Q2 results. Ranpak Holdings PACK -31% on Q2 results. Teladoc Health TDOC -22% . on Q2 results. Lexicon Pharmaceuticals LXRX -21% on pricing $85M stock offering ...
Gainers: Blue Water Vaccines ( BWV ) +69% . Leafly Holdings ( LFLY ) +25% . AlloVir ( ALVR ) +23% . Teva Pharmaceutical ( TEVA ) +21% . Nutriband ( NTRB ) +17% . Losers: ObsEva ( OBSV ) -68% . Cassava Scie...
AlloVir ( NASDAQ: ALVR ) shares gained over 8% pre-market on Wednesday after the immunotherapy company announced a $126.6M securities offering. The firm entered into a securities purchase agreement with a group of institutional and strategic investors to sell ~25.46M s...
Proceeds Support the Completion of Three Global Phase 3 Registrational Trials for Posoleucel and Global Regulatory Filings AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered into a securities purch...
Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...